New schizophrenia drug enters early human testing
NCT ID NCT06504290
First seen Jan 07, 2026 · Last updated May 25, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug called VV119 in healthy adults and people with schizophrenia. The main goal is to check safety and how the drug moves through the body. About 40 participants will take multiple doses to see if it is well-tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anding Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Beijing Anding Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact
Contact
-
Beijing Huilongguan Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Xi'an Mental Health Center
RECRUITINGXi’an, Shanxi, China
Contact
Conditions
Explore the condition pages connected to this study.